The round attracted prominent leaders in AI and biotech, including new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.

Parallel Bio is pioneering human-first drug discovery by combining organoids and AI to create true-to-life models of human biology. The company developed the first platform that replicates the human immune system across diverse populations, predicting drug success and identifying disease targets with accuracy and speed far beyond the limits of traditional animal models. Pharmaceutical partners, including three Fortune 500 companies, are using its Clinical Trial in a Dish to test the safety and efficacy of immunotherapies. Based in Cambridge, Mass., Parallel Bio was founded in 2021 by two scientists behind the world's first scalable human immune organoid.